Q-omics provides the consensus-scored DPF3 profile across patient tissues and cancer cell-line models. DPF3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SARC. Among the 18 cancer types available for tumor–normal comparison, DPF3 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, DPF3 RNA expression shows 17,517 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SARC, COAD, and LSCC as cancer lineages where DPF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPF3 survival associations across molecular data types. DPF3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPF3 RNA expression–survival associations across cancer types. High DPF3 expression shows unfavorable associations in SARC, MESO, COAD and LGG, but favorable associations in LIHC and ESCA. The SARC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SARC as the clearest survival context for DPF3 RNA expression.
This table summarizes DPF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DPF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPF3 shows lower tumor expression in COAD, BLCA, KIRP, LIHC and BRCA and higher tumor expression in KIRC. The COAD box plot shows higher DPF3 RNA expression in normal versus tumor tissue (log2 FC = −1.495, t-test p < 0.001).
This table shows molecular features associated with DPF3 in patient tissues and cancer cell lines. In patient samples, DPF3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DPF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
